COLOPHON / CONTACT
Contact TB-500 Medicinal: editorial inquiries and corrections.
An editorial channel for source questions and corrections. We do not provide medical advice, prescriptions, or product.
Editorial inquiries only
Contact TB-500 Medicinal for editorial matters: a question about a source, a correction to a cited figure, or a note about a study we should read. This is the working channel for an editorial digest of the TB-500 and thymosin beta-4 literature — nothing more.
We cannot help with anything clinical or commercial. We do not provide medical advice, we do not diagnose or treat, we do not prescribe, and we do not write or fill prescriptions. We do not sell, supply, source, or price TB-500 or any other substance, and we cannot point you to anyone who does. Messages asking where to buy, how to dose, or how to obtain a restricted substance will not be answered — those questions sit outside what this project does.
What to expect
Use the form below to reach the editorial desk. Tell us which page and which claim you are writing about, and include the source you are referencing if you are flagging a correction. We read every message about the accuracy of the record and prioritize anything that suggests a cited figure, a molecule tag, or a regulatory statement is wrong.
For regulatory questions, note that the legal-status page reflects the FDA record as verified at the dates cited there; the status can change through processes like the scheduled July 2026 PCAC review, and we update the page against the source rather than against secondhand reports. If you believe a regulatory line is out of date, the most useful thing you can send is the authoritative FDA page that supersedes it.